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Abstract
Taxotere showed antitumor activity against solid
tumors including prostate cancer. However, the mo-
lecular mechanism(s) of action of Taxotere has not
been fully elucidated. In order to establish such
molecular mechanism(s) in both hormone-insensitive
(PC3) and hormone-sensitive (LNCaP) prostate cancer
cells, comprehensive gene expression profiles were
obtained by Affymetrix Human Genome U133A Array.
The RNA from the cells treated with 2 nM Taxotere was
subjected to microarray analysis. We found that a total
of 166, 365, and 1785 genes showed greater than two-
fold change in PC3 cells after 6, 36, and 72 hours of
treatment, respectively compared to 57, 823, and 964
genes in LNCaP cells. The expression of tubulin was
decreased, whereas the expression of microtubule-
associated proteins was increased in Taxotere-treated
prostate cancer cells, confirming the microtubule-
targeting effect of Taxotere. Clustering analysis
showed downregulation of some genes for cell
proliferation and cell cycle. In contrast, Taxotere
upregulated some genes that are related to induction
of apoptosis and cell cycle arrest. From these results,
we conclude that Taxotere caused alterations of a
large number of genes, many of which may contribute
to the molecular mechanism(s) by which Taxotere
affects prostate cancer cells. Further molecular stud-
ies are needed in order to determine the cause and
effect relationships between these genes altered by
Taxotere. Nevertheless, our results could be further
exploited for devising strategies to optimize therapeu-
tic effects of Taxotere for the treatment of prostate
cancer.
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Introduction
Taxotere is a semisynthetic anticancer agent derived from
baccatin III of the needles of Taxus baccata. It has shown a
wide spectrum of cytotoxicity for various solid tumors as
well as clinical activity when used for the treatment of breast,
lung, ovarian, and prostate cancers. In early-stage and meta-
static breast, lung, and ovarian cancers, randomized trials have
shown that Taxotere-containing therapies are superior to, or as
effective as, established standard chemotherapeutic regimens
and are often associated with an improved safety profile [1–3].
Recent clinical trials have found that weekly Taxotere in
patients with metastatic hormone-refractory prostate cancer
is associated with improvements in clinical benefit response
and quality of life, and is well tolerated [4,5]. Thus, Taxotere is
currently considered to be among the most important antican-
cer drugs in cancer chemotherapy. Its known basic mechanism
of action is that it binds to tubulin and deranges the equilibrium
betweenmicrotubule assembly and disassembly during mitosis
[6]. Stabilization of microtubules by Taxotere impairs mitosis
and exerts an anticancer effect in tumors [6]. Recent inves-
tigations suggest that Taxotere acts by additional mechanisms
that are distinct from its effects on microtubules. It has been
reported that Taxotere increases bcl-2 phosphorylation and
downregulates bcl-xl, inhibiting the antiapoptotic function of
bcl-2 family [7–9]. Avramis et al. [10] found increased p21WAF1
and p53 levels, and induced apoptosis following Taxotere
treatment in human leukemia cells. Despite its ability to induce
apoptosis, Taxotere also exhibits regulation of expression of
cytokine genes [11], suggesting the pleiotropic effects of Tax-
otere on human cancers.
Prostate cancer is the most common nondermatological
carcinoma in the United States with an estimated 220,900
new cases and 28,900 deaths in 2003 [12]. Up to 30% of
men undergoing radical prostatectomy will relapse, often as a
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result of micrometastatic disease present at the time of
surgery [13]. Metastatic androgen-independent prostate
cancer is an advanced stage of prostate cancer and,
unfortunately, conventional chemotherapeutic agents have
not been, thus far, effective for metastatic prostate cancer.
Therefore, there is a tremendous need for the development
of mechanism-based and targeted strategies for the treat-
ment of prostate cancer. Microarray permits rapid analysis
of the expression of a large number of genes and, in turn,
provides an opportunity for determining the effects of
anticancer agents on cancer cells. The alterations of gene
expression profiles by several anticancer agents have been
reported [14,15]. The data from microarray are likely
to contribute in devising therapeutic strategies more accu-
rately, and will help to determine the molecular mecha-
nism(s) of action of therapeutic agents.
Yoo et al. [16] have reported Taxotere-induced gene
expression patterns in head and neck cancer cells by using
cDNA microarray, which contains 1191 genes. They found
that Taxotere regulated some genes that are related to cell
cycle, apoptosis, angiogenesis, and tyrosine kinase signal
transduction. However, little is known regarding the gene
expression profiles of prostate cancer cells after Taxotere
treatment. In addition, the precise molecular mechanism(s)
by which Taxotere exerts its tumor-suppressive effects on
prostate cancer is unclear. Hence, in this study, we utilized
the high-throughput gene chip, which contains 22,215 known
genes, to determine the alteration of gene expression pro-
files of hormone-insensitive (PC3) and hormone-sensitive
(LNCaP) prostate cancer cells exposed to Taxotere.
Materials and Methods
Cell Culture and Growth Inhibition
PC3 (ATCC, Manassas, VA) and LNCaP (ATCC) human
prostate cancer cells were cultured in RPMI-1640 media
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum and 1% penicillin and streptomycin in a 5%
CO2 atmosphere at 37jC. Taxotere (Aventis Pharmaceut-
icals, Bridgewater, NJ) was dissolved in DMSO to make
4 mM stock solution. For growth inhibition, PC3 and LNCaP
cells were seeded at a density of 5 104 per well in a six-well
culture dish. After 24 hours, the cells were treated with 1, 2,
and 4 nM Taxotere. Control PC3 and LNCaP cells received
0.01% DMSO for same time points. Cells treated with
Taxotere or DMSO for 1 to 3 days were harvested by
trypsinization, stained with 0.4% trypan blue, and counted
using a hemocytometer. The concentrations of Taxotere
used for our in vitro studies are easily achievable in humans,
suggesting that our experimental results are relevant for
human applications. The experiment was repeated three
times and a t-test was performed to verify the significance
of cell growth inhibition after treatment.
Microarray Analysis for Gene Expression Profiles
PC3 and LNCaP cells were treated with 2 nM Taxotere for
6, 36, and 72 hours. Total RNA from each sample was
isolated by Trizol (Invitrogen) and purified by RNeasy Mini
Kit and RNase-free DNase Set (Qiagen, Valencia, CA)
according to the manufacturer’s protocols. cDNA for each
sample was synthesized by using Superscript cDNA Syn-
thesis Kit (Invitrogen) using the T7-(dT)24 primer instead of
the oligo(dT) provided in the kit. Then, the biotin-labeled
cRNA was transcripted in vitro (IVT) from cDNA by using
BioArray High-Yield RNA Transcript Labeling Kit (Enzo Bio-
chem, New York, NY), and purified by RNeasy Mini Kit. After
fragmentation, the fragmented labeled cRNA was applied to
Human Genome U133A Array (Affymetrix, Santa Clara, CA),
which contains 22,215 human gene probes, and hybridized
to the probes in the array. After washing and staining, the
arrays were scanned. Two independent experiments were
performed to verify the reproducibility of results. Correlation
statistical analysis for the data obtained from the two experi-
ments was accessed by using Pearson product moment
correlation coefficient.
Microarray Data Normalization and Analysis
The gene expression levels of samples were normalized
and analyzed by using Microarray Suite, MicroDB, and Data
Mining Tool software (Affymetrix). The absolute call (pres-
ent, marginal, and absent) and average difference of 22,215
gene expressions in a sample, and the absolute call differ-
ence, fold change, and average difference of gene expres-
sions between two or several samples were also normalized
and identified using these software. Statistical analysis of the
mean expression average difference of genes, which show
greater than two-fold change, was performed using a t-test
between treated and untreated samples. Clustering and
annotation of the gene expression were analyzed by using
Cluster, TreeView [17], Onto-Express [18], and GenMAPP
(www.genmapp.org). Genes that were not annotated or not
easily classified were excluded from the functional clustering
analysis.
Real-Time Reverse Transcription Polymerase Chain
Reaction (RT-PCR) Analysis for Gene Expression
To verify the alterations of gene expression at the mRNA
level, which appeared on the microarray, we chose 23
representative genes (Table 1) with varying expression
profiles for real-time RT-PCR analysis. Two micrograms of
total RNA from each sample was subjected to reverse
transcription using the Superscript first-strand cDNA synthe-
sis kit (Invitrogen) according to the manufacturer’s protocol.
Real-time PCR reactions were then carried out in a total of
25 ml of reaction mixture (2 ml of cDNA, 12.5 ml of 2  SYBR
Green PCR Master Mix, 1.5 ml of each 5 mM forward and
reverse primers, and 7.5 ml of H2O) in an ABI Prism 7700
Sequence Detection System (Applied Biosystems, Foster
City, CA). The PCR program was initiated by 10 minutes at
95jC before 40 thermal cycles, each of 15 seconds at 95jC
and 1 minute at 60jC. Data were analyzed according to the
comparative Ct method and were normalized by actin ex-
pression in each sample. Melting curves for each PCR
reaction were generated to ensure the purity of the amplifi-
cation product.
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Western Blot Analysis
In order to verify whether the alterations of genes at the
level of transcription ultimately result in the alterations at
the level of translation, we conducted Western blot analysis
for selected genes with varying expression profiles. The
PC3 and LNCaP cells were treated with 1 and 2 nM
Taxotere for 24, 48, and 72 hours. After treatment, the
cells were lysed and protein concentration was measured
using BCA protein assay (Pierce, Rockford, IL). The pro-
teins were subjected to 10% or 14% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
and electrophoretically transferred to nitrocellulose mem-
brane. The membranes were incubated with anti-
p21WAF1 (1:500; Upstate, Lake Placid, NY), anti-p27KIP1
(1:250; Novocastra, Newcastle upon Tyne, UK), anti-Bax
(1:10000; Trevigen, Gaithersburg, MD), anti-survivin
(1:200; Alpha Diagnostic, San Antonio, TX), anti –cell
division cycle (CDC) 2 (1:200; Santa Cruz, Santa Cruz,
CA), anti–cyclin A (1:250; NeoMarkers, Union City, CA),
anti – cyclin E (1:250; NeoMarkers), and anti –h-actin
(1:10000; Sigma, St. Louis, MO) primary antibodies, and
subsequently incubated with secondary antibody conjugat-
ed with fluorescence dye. The signal was then detected
and quantified by using Odyssey infrared imaging system
(LI-COR, Lincoln, NE). The ratios of p21WAF1, p27KIP1,
Bax, survivin, CDC2, cyclin A, or cyclin E against h-actin
were calculated by standardizing the ratios of each control
to the unit value.
Results
Cell Growth Inhibition by Taxotere Treatment
Cell growth inhibition assay showed that the treatment
of PC3 and LNCaP prostate cancer cells with Taxotere
resulted in a dose- and time-dependent inhibition of cell
proliferation (Figure 1), demonstrating the growth-inhibitory
effect of Taxotere on prostate cancer cells. Inhibition of cell
proliferation observed by cell growth inhibition assay could
be due to altered regulation of gene expression by Tax-
otere treatment. We further investigated the gene expres-
sion profiles of PC3 and LNCaP prostate cancer cells
treated with Taxotere.
Table 1. The Primers Used for Real-Time RT-PCR Analysis.
Genes Primer Sequence PCR Product (bp)
a-Tubulin gct ttg gtg ggg gaa ct 104
cgc cgg gta aat aga gaa ct
a1-Tubulin cgg tct tca ggg ctt ctt gg 139
ctg ggg tgc tgg gta aat gg
b5-Tubulin ccg cag aag agg agg agg att 120
gga gag gaa agg ggc agt tga
CHK1 tag ata tga agc gtg ccg tag 113
gcc ttc tct cct gtg acc a
Cyclin A2 aat cag ttt ctt acc caa tac 127
ctg atg gca aat act tga
Fas/Apo-1 caa aag tgt taa tgc cca agt 187
gca gtc tgg ttc atc cc
FOXM1 gcc aca ctt agc gag acc c 189
atc aca agc att tcc gag aca
GADD45 cgc ctg tga gtg agt gc 154
ctt atc cat cct ttc ggt ctt
IGFBP2 atg ggc gag ggc act t 189
cag ctc ctt cat acc cga ctt
IMPA2 tga ccc tgc gac cct gaa 197
cgc ctg ctt ctc tga tga tga
Ki-67 ccg ggc tcc atc atc t 148
ctc cag acg cca aaa taa gac
Microtubule-related gga gat gtc tat tgc cga gta 164
protein acc cca aac caa aca cc
p21WAF1 ctg gag act ctc agg gtc gaa 98
gga tta ggg ctt cct ctt gga
p27KIP1 cgc tcg cca gtc cat t 187
aca aaa ccg aac aaa aca aag
PIR cac tag ccc tcc atc ctc tac 151
ggg tct gcc aat gct tct
RANBP1 ttc cga ttt gcc tct gag aac 153
cgg cgt gat gta gtg gtt g
STK6 tca gcg ggt ctt gtg t 162
ctc ttt tgg gtg tta ttc agt
Survivin cca ctg ccc cac tga gaa c 118
acc gga cga atg ctt ttt atg
TRIP13 tct ggc agt gga caa gca gtt 136
tgg gag acg gct gtg tgg
TBP cac gaa cca cgg cac tga tt 96
ttt tct tgc tgc cag tct gga c
b-Actin cca cac tgt gcc cat cta cg 99
agg atc ttc atg agg tag tca gtc ag
Figure 1. Effects of Taxotere on the growth of PC3 and LNCaP cells. PC3
and LNCaP prostate cancer cells treated with Taxotere resulted in a dose-
and time-dependent inhibition of cell proliferation (*P < .05, n = 3).
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Alteration of Global Gene Expression by Taxotere Treatment
The alterations of gene expression were observed as
early as 6 hours and were more evident with more genes
altered after longer treatment (Figure 2). A total of 166,
365, and 1785 genes showed greater than two-fold change
in PC3 cells after 6, 36, and 72 hours of Taxotere
treatment, respectively compared to 57, 823, and 964
genes in LNCaP cells treated with Taxotere for the same
time point. The results of real-time RT-PCR analysis for
selected genes were in direct agreement with the micro-
array data (Figure 3; Table 2). The same alterations of
gene expression were observed by real-time RT-PCR
analysis, although the fold change in the expression level
was not exactly similar between these two different ana-
lytical methods. furthermore, the results of western blot
analysis also are in direct agreement with the microarray
and RT-PCR data (Figure 4). These results suggest that
Taxotere regulates the transcription and translation of
genes that are involved in the processes of cell survival
and physiological behaviors.
The altered genes were subjected to cluster analysis
according to the location and cellular components. The genes
showing altered expression were mostly located on chromo-
somes 1, 2, 6, 12, 17, and 19, andweremainly responsible for
the transcription and translation of components of the nucle-
us, cytoplasm, and integral plasma membrane proteins.
Taxotere exerted differential effects on gene expression
profiles between PC3 and LNCaP cells. However, we found
no effect of Taxotere on the expression of androgen receptor
(AR), although upregulation of several genes involved in
steroid-independent AR activation [insulin-like growth factor
binding protein (IGFBP) 2, fibroblast growth factor (FGF) 13,
and epidermal growth factor (EGF) 8] was observed in
LNCaP cells (Table 2). This interesting observation needs
further in-depth investigation and is currently ongoing in our
laboratory.
Figure 2. Cluster analysis of genes showing alterations in mRNA expression after Taxotere treatment. The alterations of specific genes are shown.
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Regulation of Microtubule-Related Genes by Taxotere
Treatment
By using microarray, GenMAPP computerized analysis,
and RT-PCR, we found that Taxotere downregulated the
expression of tubulins including tubulin a1, tubulin a6, tubulin
h2, and tubulin h5 (Table 2; Figures 2 and 5), suggesting the
inhibitory effect of Taxotere on microtubule. We also found
that Taxotere upregulated the expression of microtubule-
associated proteins (Table 2; Figures 2 and 5), suggesting
the effects of Taxotere on microtubule assembly.
Regulation of Genes Involved in Cell Cycle and Apoptotic
Process
After clustering based on biological function using Onto-
Express and GenMAPP computerized analysis, we found
that in both PC3 and LNCaP cells, Taxotere downregulated
the expression of some genes, which are critically involved in
the regulation of cell proliferation and cell cycle (Table 2;
Figures 2 and 6). In contrast, Taxotere upregulated the
expression of some genes that are related to induction of
apoptosis and cell cycle arrest (Table 2; Figures 2 and 6).
Western blot analysis showed that the protein levels of
p21WAF1 and Bax in LNCaP cells treated with Taxotere were
upregulated, whereas survivin, CDC2, cyclin A, and cyclin E
were downregulated (Figure 4). In Taxotere-treated PC3
cells, the protein levels of p21WAF1 and p27KIP1 were upre-
gulated, and survivin, cyclin A, and cyclin E were down-
regulated. These results are novel and have not been
reported previously. However, further mechanistic studies
are needed in order to establish cause-and-effect relation-
ships between these genes with apoptosis-inducing effect of
Taxotere in prostate cancer cells.
In addition to the effects of Taxotere on microtubule, cell
cycle, and apoptosis, Taxotere also showed the regulation
of genes related to signal transduction, transcription factor,
oncogenesis, and tumor suppression (Table 2; Figure 2).
Discussion
Microtubules are formed from a-tubulin and h-tubulin, and
their polymerization and depolymerization are complex and
interesting processes with important biological roles [19].
The mitotic spindle, one of the microtubules, forms after the
cytoplasmic microtubules disassemble during mitosis. It
has been known that Taxotere binds tightly to microtubules
and stabilizes them, causing mitotic arrest in cancer cells
[6]. Taxotere also induces apoptosis through inhibition of
the depolymerization of microtubules [20]. However, the
precise molecular mechanism is still unknown. In the
present study, we found that Taxotere inhibited the expres-
sion of a-tubulin and h-tubulin, in addition to stabilizing
microtubules. In contrast, the expression of microtubule-
associated proteins was upregulated after Taxotere treat-
ment. Microtubule-associated proteins are a family of
proteins, which are involved in the regulation of microtu-
bule assembly and used as a marker of differentiation
[21]. Upregulation of microtubule-associated proteins by
Taxotere treatment will promote stabilization of microtu-
bules and differentiation of cells, whereas downregulation
of tubulin will lead to insufficiency of material for mitotic
spindle formation, resulting in the cell cycle arrest of
cancer cells (Figure 6). This may be another molecular
mechanism by which Taxotere exerts its growth-inhibitory
effect on cancer cells.
Figure 3. Real-time RT-PCR amplification curves showing the altered expression of specific genes from RNA of Taxotere-treated PC3 and LNCaP cells. Real-time
RT-PCR melting curve showing that the PCR product is pure (only one peak).
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Table 2. Fold Changes of Specific Genes in PC3 and LNCaP Cells Treated with Taxotere.
Genes PC3 LNCaP
6 hours 36 hours 72 hours 6 hours 36 hours 72 hours
Tubulin and microtubule-related
BC004188.1 tubulin, h2 NC* 1y 1.3 1.4 3.2 3.5
AF141349.1 h-tubulin mRNA NC 1 1.2 1.3 3.7 4.9
BC004949.1 tubulin a6 1.1 0.8 1.5 1.3 2.6 3
BC006379.1 tubulin a1 1.2 0.8 1.3 1.2 3.5 4
BC005838.1 tubulin, h5 NC 0.9 1.2 1.3 4 4.3
AL565074 tubulin, a1 NC 0.8 1.5 1.1 4.9 4.9
BC001002.1 tubulin, h 1.1 1.9 2 1 2.8 3.2
AL581768 Tubulin, a NC 0.9 1.2 1.5 4 4.9
AA515698 tubulin, h2 NC 0.9 1.5 1.3 3 3
NM 012155.1 microtubule-associated protein like echin 1.1 1.7z 2.6 1.3 3.2 3.2
AF183417.1 microtubule-associated proteins 1A1B NC 1.5 3 1.1 2 1.6
Cell cycle
NM 006739.1 cell division cycle 46 1 0.9 2.6 1.4 45.3 36.8
NM 021873.1 cell division cycle 25B (CDC25B) 1.3 0.9 2 1.1 1.6 2.5
NM 004526.1 mitotin mRNA NC 0.8 2.3 1.1 5.7 8
NM 000075.1 cyclin-dependent kinase 4 (CDK4) NC 0.8 2.3 1.1 1.4 1.4
NM 000389.1 cyclin-dependent kinase inhibitor p21 (Waf1) 1.7 1.7 2.6 1.3 9.8 8.6
NM 001255.1 CDC20 (CDC20) NC NC 1.4 1.9 9.5 47
NM 001786.1 cell division cycle 2 (CDC2) NC NC 1.3 1.2 7.5 12.1
NM 001237.1 cyclin A2 (CCNA2) NC 0.9 2 1.2 5.7 12.1
NM 003503.2 CDC7 (cell division cycle 7) 1.2 0.9 1.8 NC 2.1 2.3
U17105.1 cyclin F mRNA NC 0.7 2.1 1.6 11.3 11.3
NM 004702.1 cyclin E2 (CCNE2) 1.8 0.9 2 1.6 5.3 3.2
NM 006806.1 BTG family, member 3 (BTG3) 1.3 1.2 1.6 1.1 1.6 2.1
AI765445 BTG family, member 3 1.3 1.2 1.6 1.2 1.7 2.1
BC001971.1 cyclin-dependent kinase inhibitor p27 (Kip1) 1.1 1.6 2.3 1.2 1.1 1.2
AI251890 CDC-like kinase 1 1.1 1.5 4.9 NC 1.7 2.1
Apoptosis
NM 001168.1 survivin mRNA 1.2 1 1.5 1.1 20.9 24.1
NM 001924.2 GADD45A mRNA 1.1 2.3 4.3 1.4 7.5 7.5
NM 001455.1 forkhead box O3A (FOXO3A) NC 1 1.4 1.1 2 2.1
AB028869.1 survivin-h NC NC 1.3 1.1 1.3 4.9
U72398 Bcl-xh (bcl-x) gene NC NC 1.5 NC 1.6 2.1
X83493.1 Fas/Apo-1 NC 1.1 1.1 1.1 4.6 8
AF082283.1 CARD-containing apoptotic signaling protein NC 2 2.3 1.1 1.3 2
NM 001197.2 BCL2-interacting killer (apoptosis-inducing) 1.4 1.2 1.7 1.1 2.6 2.6
NM 004324.1 BCL2-associated X protein (BAX) 1.1 0.8 1.4 1.3 3.2 3
U19599.1BAX y mRNA 1.1 NC NC 1.1 2.8 4.3
Oncogenesis
NM 006342.1 acidic coiled coil containing protein 3 (TACC3) 1.3 NC 1.6 1.2 11.3 45.3
NM 005030.1 polo-like kinase (PLK) NC 0.9 1.6 1.4 5.3 5.3
NM 014264.1 serine/threonine kinase 18 (STK18) 1.3 0.9 1.9 1.4 8.6 16
NM 001274.1 CHK1 1.1 0.8 2 1.1 4.3 7
AU152107 Ki-67 1.2 0.8 3.3 NC 1.6 2.3
NM 003600.1 serine/threonine kinase 15 (STK15) 1.3 NC 1.5 1.2 3.7 8.6
NM 003158.1 serine/threonine kinase 6 (STK6) 1.2 1.1 1.7 1.7 11.3 9.8
Transcription
NM 021953.1 forkhead box M1 (FOXM1) NC 0.8 2.1 1.2 13.9 32.2
NM 004237.1 thyroid hormone receptor interactor 13 (TRIP13) NC NC 1.7 1.1 4.9 3.5
NM 007295.1 breast cancer 1, early onset (BRCA1) 1.1 NC 1.4 1.2 1.7 24.3
NM 005225.1 E2F transcription factor 1 (E2F1) NC 0.8 2.6 NC 9.2 13.9
NM 002128.1 high-mobility group protein 1 (HMG1) NC 0.9 1.7 1.1 2 2.1
NM 005342.1 high-mobility group protein 4 (HMG4) 1.3 1.1 1.7 1.1 2.1 2.6
NM 003662.1 Pirin (PIR) 1.2 1.6 2.6 NC 2.5 3.5
NM 006166.2 nuclear transcription factor Y, h (NFYB) NC NC 1.5 NC 2.5 1.2
Androgen receptor – related
NM 000597.1 insulin-like growth factor binding protein 2 1 1.1 1.3 NC 1.5 2.1
NM 004114.1 fibroblast growth factor 13 (FGF13) 1 1.6 1.9 NC 2.3 2.8
BC003610.1 globule EGF factor 8 NC NC 2.2 1.1 1.9 2.6
*No change.
yNegative value, decrease.
zPositive value, increase.
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It has been found that CDCs regulate the molecules
related to the cell cycle, and they are essential and important
for the initiation and progression of successive phases of the
cell cycle [22,23]. It has been well known that cyclins
associate with cyclin-dependent protein kinases (CDKs)
and CDCs to control the process of cell cycle [24–27]. The
CDK inhibitors including p21WAF1 and p27KIP1 have been
demonstrated to arrest the cell cycle and inhibit the growth of
Figure 4.Western blot analysis of selected gene expression in Taxotere-treated LNCaP cells at the protein level. (A) The expression of survivin was downregulated
with Taxotere treatment. (B) The expression of p21WAF1 was upregulated with Taxotere treatment. (C) The expression of CDC2 was downregulated with Taxotere
treatment. (D) The expression of Bax was upregulated with Taxotere treatment.
Figure 5. Effect of Taxotere on microtubule-related gene expression analyzed and visualized by GenMAPP software integrated with cDNA microarray data
(positive value: increase in fold change; negative value: decrease in fold change).
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cancer cells [28,29]. Our results showed that cyclins (cyclin
A2, cyclin E2, and cyclin F), CDK4, and CDCs (CDC2,
CDC 7, CDC20, and CDC25B) were downregulated in
Taxotere-treated prostate cancer cells, whereas CDK inhib-
itors (p21WAF1 and p27KIP1) were upregulated, suggesting
that Taxotere inhibited the growth of both hormone-insensi-
tive and hormone-sensitive prostate cancer cells through the
arrest of the cell cycle and inhibition of proliferation (Figure 6).
These observations are novel in Taxotere-treated prostate
cancer cells. Similar effects on cell cycle were also observed
in Taxotere-treated head and neck cancer cells [16], sug-
gesting some common mode of action of Taxotere in cancer
cells. However, most of the altered genes by Taxotere in
head and neck cancer cells are different from our data,
reflecting the different cellular context; hence, the mode of
action of Taxotere in prostate cancer cells is unique and has
not been reported previously.
Inhibition of cell growth by Taxotere could also be due
to the induction of apoptosis in addition to cell cycle arrest.
It has been reported that Taxotere is able to induce apo-
ptosis through caspase-3–dependent or caspase-3–inde-
pendent cell death mechanism [30]. We found a decreased
level of survivin and increased level of growth arrest and
DNA damage gene 45A (GADD45A), Fas/Apo-1, and fork-
head transcription factor FKHR-L1 (FOXO3A), all of
which are related to apoptotic processes, and these
effects of Taxotere have not been previously reported.
Survivin is overexpressed in a variety of cancer cells.
Xia et al. [31] reported that antisurvivin oligonucleotides
induced apoptosis in mesothelioma cells, suggesting that
downregulation of survivin appears to be an effective
therapy for mesothelioma. It has been known that
GADD45 promotes apoptosis and regulates G2/M arrest
[32]. Fas/Apo-1 and FOXO3A also induce apoptosis
[33,34]. Induction of apoptosis by FOXO3A has been
correlated with the disruption of mitochondrial membrane
integrity, cytochrome c release, and upregulation of Bim
[35]. Taxotere regulated the expression of survivin,
GADD45A, Fas/Apo-1, and FOXO3A in prostate cancer
cells, suggesting its effect on induction of apoptosis
(Figure 6). The induction of apoptosis mediated by these
molecules could be additional molecular mechanism(s) by
which Taxotere exerts its growth-inhibitory effects on
prostate cancer cells.
We found that Taxotere also inhibited the expression of
transcription factors [high-mobility group protein (HMG) 1,
HMG4, nuclear factor-Y (NF-Y) B, and pirin], serine/thre-
onine kinase 15 (STK15), checkpoint kinase 1 (Chk1),
polo-like kinase (PLK), and transforming acidic coiled coil
containing protein 3 (TACC3), which have been related to
oncogenesis [36–39]. In contrast, it upregulated the ex-
pression of tumor-suppressor genes including p21WAF1,
p27KIP1, and N-myc downregulated gene 1 (NDRG1).
These results are novel, and suggest that Taxotere may
inhibit cancer cell growth and survival through inhibition of
transcription and oncogenesis.
Figure 6. Effects of Taxotere on cell cycle – and apoptosis pathway– related gene expression analyzed and visualized by GenMAPP software integrated with
cDNA microarray data (positive value: increase in fold change; negative value: decrease in fold change).
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Taxotere showed differential effects on gene expression
profiles between androgen-insensitive PC3 cells and andro-
gen-sensitive LNCaP cells. We observed significant alter-
ation in the expression of CDC46, survivin, TACC3, and
forkhead box transcription factor M1 (FOXM1) in Taxotere-
treated LNCaP cells compared to PC3 cells, suggesting that
LNCaP cell is more sensitive to Taxotere-induced apoptosis.
These results are consistent with published data from other
investigators showing that different Taxotere-induced apo-
ptotic pathways exist in LNCaP and PC3 prostate cancer cell
lines [40]. Because Taxotere showed no effect on AR in
LNCaP cells, it is likely that Taxotere may exert its growth-
inhibitory effects on prostate cancer through AR-independent
pathways. Further in-depth studies are needed to address
this issue, particularly the gene regulation by Taxotere in
hormone-responsive and nonresponsive prostate cancers.
Nevertheless, Taxotere inhibited cell growth in both andro-
gen-insensitive PC3 cells and androgen-sensitive LNCaP
cells through regulation of gene expression related to control
of cell proliferation, cell cycle, apoptosis, transcription factor,
and oncogenesis, suggesting that Taxotere may be used for
the treatment of prostate cancer including advanced hor-
mone-insensitive prostate cancer.
In conclusion, Taxotere directly and indirectly caused
changes in the expression of a large number of genes that
are critically involved in the control of cell survival, cell
physiological behaviors, and oncogenesis. This information
may provide novel additional molecular mechanism(s) by
which Taxotere exerts its pleiotropic effects on prostate
cancer cells. These results could be important in devising
mechanism-based and targeted therapeutic strategies for
prostate cancer, especially in devising combination therapy
with Taxotere and other chemotherapeutic agents based on
the molecular mechanism(s). However, further in-depth in-
vestigation is needed in order to establish cause-and-effect
relationships between these altered genes with apoptosis-
inducing effect of Taxotere in prostate cancer cells.
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